Promontory Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1350 Avenue of the Americas Fl 23, New Y...Phone Number
(646) 380-2441Website
www.promontorytx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Promontory Therapeutics
Promontory Therapeutics was founded by two entrepreneurs in 2010, with headquarters located in New York City. Since that time, the company has built inter-disciplinary teams both internally and externally and conducted collaborations globally. The company is an independent and privately funded company, and hold the exclusive global license to a novel family of compounds that includes the company's lead agent, PT-112. The company's Research and Development efforts comprise university and pharmaceutical industry collaborators in the US, Europe, Japan and China; and drug manufacturing in both the US and Europe. The company is currently in Phase 2 clinical development with three ongoing studies in solid tumors and have completed Phase 1 in hematological oncology. Notably, the company has received Orphan Drug designation for Thymoma and Multiple Myeloma.Explore more
Promontory Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Promontory Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Promontory Therapeutics launches new products
Check out if Promontory Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Promontory Therapeutics recently announced quarterly report
Promontory Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Promontory Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Promontory Therapeutics
Funding: Get notified immidiatlly once Promontory Therapeutics has new funding data
Click to see if Promontory Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Promontory Therapeutics
Find 2 more new buyers
Compare Similar Companies to Promontory Therapeutics
Compare insights from companies similar to Promontory Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Promontory Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Promontory Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Promontory Therapeutics.
Promontory Therapeutics Tech Stack
A closer look at the technologies used by Promontory Therapeutics
Promontory Therapeutics News & Media
Promontory Therapeutics Enrolls 109 Patients in Prostate Cancer Study
By Daniella Parra Promontory Therapeutics Inc. completed enrollment of 109 late-stage metastatic castration-resistant prostate cancer patients for its Phase 2 trial of PT-112, which assesses its efficacy in patients who have undergone prior treatments, the company said. PT-112 is a promising small-molecule conjugate of pyrophosphate, notable for its tolerability and ability to induce immunogenic cell […]Promontory Therapeutics Completes Enrollment of Phase 2 Trial of PT-112 in Late-Line Patients with Metastatic Castration-Resistant Prostate Cancer
Ongoing clinical trial has reached target enrollment of 109 patients across clinical sites in the United States and France Open-label dose optimization and proof of concept study of PT-112 monotherapy includes interim data results, with top-line read-out and conference presentations...Promontory Therapeutics Gives Results on Cancer Treatment Candidate PT-112
By Karen E. Roman Promontory Therapeutics Inc., a clinical stage development company centered on small molecule immunotherapy in cancer, presented its latest results on its lead therapeutic candidate, PT-112. The results were exposed at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, from November 1-5, 2023. Data shows PT-112 […]Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects
PT-112's mechanism of action inhibits ribosomal biogenesis, promoting immunogenic cancer cell death through cancer cell organelle stresses Data presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting NEW YORK, Nov. 4, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Promontory Therapeutics
Sign Up For FreeTo access detailed company insights
Promontory Therapeutics was founded by two entrepreneurs in 2010, with headquarters located in New York City. Since that time, the company has built inter-disciplinary teams both internally and externally and conducted collaborations globally. The company is an independent and privately funded company, and hold the exclusive global license to a nov... Read More
